Serological surveillance and IL-10 genetic variants on anti-HBs titers: Hepatitis B vaccination 20years after neonatal immunization in Taiwan

Clinica Chimica Acta

Volumn 412, Issue 9-10, 2011, Pages 766-773

  Lin, Ying Ju ^a,b   Lan, Yu Ching ^b   Wan, Lei ^a,b   Lin, Ting Hsu ^a   Chen, Da Yuan ^a   Tsai, Chang Hai ^c   Liu, Chiu Shong ^a   Hsueh, Kai Chung ^d   Tsai, Fuu Jen ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d Taichung Hospital   (Taiwan)

Author keywords

Hepatitis B; IL 10 genetic polymorphisms; Vaccine

Indexed keywords

ADENINE; CYTOSINE; GLUCOSE; GUANINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 10; THYMINE;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRADUATE STUDENT; HAPLOTYPE; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SYSTOLIC BLOOD PRESSURE; TAIWAN; UNIVERSITY HOSPITAL;

ADOLESCENT; ALLELES; ANTIBODIES, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD, PRESCHOOL; FEMALE; HAPLOTYPES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; INFANT, NEWBORN; INTERLEUKIN-10; MALE; POLYMORPHISM, GENETIC; RISK FACTORS; SEROLOGIC TESTS; STUDENTS; TAIWAN; TIME FACTORS; UNIVERSITIES; VACCINATION; YOUNG ADULT;

EID: 79951724948     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.006     Document Type: Article

References (47)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
2. Hoofnagle J.H., di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 1997, 336:347-356.
3. Chen D.S., Sung J.L. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepato-gastroenterol (Stuttg) 1978, 25:423-430.
4. Ni Y.H., Chang M.H., Huang L.M., et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15years after mass hepatitis B vaccination. Ann Intern Med 2001, 135:796-800.
5. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855-1859.
6. Ni Y.H., Huang L.M., Chang M.H., et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007, 132:1287-1293.
7. Shokri F., Jafarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. Vaccine 2001, 19:4544-4548.
8. Belloni C., Tinelli C., Orsolini P., et al. Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth. A parallel evaluation of rubella and tetanus vaccine. Vaccine 1998, 16:399-402.
9. Lu J.J., Cheng C.C., Chou S.M., Hor C.B., Yang Y.C., Wang H.L. Hepatitis B immunity in adolescents and necessity for boost vaccination: 23years after nationwide hepatitis B virus vaccination program in Taiwan. Vaccine 2009, 27:6613-6618.
10. Lu C.Y., Ni Y.H., Chiang B.L., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18years after neonatal immunization. J Infect Dis 2008, 197:1419-1426.
11. Yucesoy B., Johnson V.J., Fluharty K., et al. Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine 2009, 27:6991-6997.
12. Lalani I., Bhol K., Ahmed A.R. Interleukin-10: biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol 1997, 79:469-483.
13. Rousset F., Garcia E., Defrance T., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992, 89:1890-1893.
14. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
15. Suarez A., Lopez P., Mozo L., Gutierrez C. Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1605-1610.
16. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
17. Crawley E., Kay R., Sillibourne J., Patel P., Hutchinson I., Woo P. Polymorphic haplotypes of the interleukin-10 5'flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999, 42:1101-1108.
18. Lazarus M., Hajeer A.H., Turner D., et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997, 24:2314-2317.
19. Kube D., Platzer C., von Knethen A., et al. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995, 7:1-7.
20. Yee L.J., Tang J., Gibson A.W., Kimberly R., Van Leeuwen D.J., Kaslow R.A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001, 33:708-712.
21. Miyazoe S., Hamasaki K., Nakata K., et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002, 97:2086-2092.
22. Hohler T., Reuss E., Freitag C.M., Schneider P.M. A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology 2005, 42:72-76.
23. Hsu H.M., Lu C.F., Lee S.C., Lin S.R., Chen D.S. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 1999, 179:367-370.
24. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
25. Chien Y.C., Jan C.F., Kuo H.S., Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20years after it was launched. Epidemiol Rev 2006, 28:126-135.
26. Chen H.L., Chang M.H., Ni Y.H., et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. Jama 1996, 276:906-908.
27. Lin H.H., Wang L.Y., Hu C.T., et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003, 69:471-474.
28. Su F.H., Chen J.D., Cheng S.H., Sung K.Y., Jeng J.J., Chu F.Y. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat 2008, 15:14-19.
29. Chang M.H. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007, 12:160-167.
30. Stevens C.E., Beasley R.P., Tsui J., Lee W.C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771-774.
31. Beasley R.P., Hwang L.Y. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983, 147:185-190.
32. Beasley R.P., Trepo C., Stevens C.E., Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977, 105:94-98.
33. Lu C.Y., Chiang B.L., Chi W.K., et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15years after neonatal vaccination. Hepatology 2004, 40:1415-1420.
34. Hu W.G., Wei J., Xia H.C., et al. Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins. World J Gastroenterol 2005, 11:2088-2094.
35. Chen X., Li M., Le X., Ma W., Zhou B. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection. Vaccine 2004, 22:439-446.
36. Mutwiri G., Benjamin P., Soita H., Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 2008, 26:2680-2688.
37. Rendi-Wagner P., Shouval D., Genton B., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006, 24:2781-2789.
38. Chen H., Deng Y., Tan W., et al. Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S+preS1 fusion antigen in Balb/C mice. Sheng Wu Gong Cheng Xue Bao 2010, 26:74-78.
39. Mizrahi M., Lalazar G., Ben Ya'acov A., et al. Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination. Vaccine 2008, 26:2589-2595.
40. Lin Y.C., Yen L.L., Chen S.Y., et al. Prevalence of overweight and obesity and its associated factors: findings from National Nutrition and Health Survey in Taiwan, 1993-1996. Prev Med 2003, 37:233-241.
41. Pan W.H., Lee M.S., Chuang S.Y., Lin Y.C., Fu M.L. Obesity pandemic, correlated factors and guidelines to define, screen and manage obesity in Taiwan. Obes Rev 2008, 9(Suppl 1):22-31.
42. Huang T.T., Kempf A.M., Strother M.L., et al. Overweight and components of the metabolic syndrome in college students. Diab Care 2004, 27:3000-3001.
43. Lao T.T., Chan B.C., Leung W.C., Ho L.F., Tse K.Y. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol 2007, 47:46-50.
44. Li-Ng M., Tropp S., Danoff A., Bini E.J. Association between chronic hepatitis B virus infection and diabetes among Asian Americans and Pacific Islanders. Dig Liver Dis 2007, 39:549-556.
45. Vangipuram S.D., Yu M., Tian J., et al. Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by fat cells. Int J Obes (Lond) 2007, 31:87-96.
46. Bouwman J.J., Visseren F.L., Bouter K.P., Diepersloot R.J. Infection-induced inflammatory response of adipocytes in vitro. Int J Obes (Lond) 2008, 32:892-901.
47. Mahnke K., Bedke T., Enk A.H. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007, 250:1-13.